EMEA Grants First Positive Opinion Under Accelerated Assessment To Soliris
This article was originally published in The Pink Sheet Daily
Executive Summary
Alexion’s treatment for a rare blood disease met CHMP’s criteria for accelerated review.
You may also be interested in...
Alexion’s Costly Soliris For AHUS Raises “Cost Of Life” Issues At NICE
NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.
Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris
The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.
Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris
The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.